Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW

Abstract Vascular endothelial growth factor-A (VEGF-A) is assumed to play a crucial role in the development and rupture of vulnerable plaques in the atherosclerotic process. We used a VEGF-A targeted fluorescent antibody (bevacizumab-IRDye800CW [bevacizumab-800CW]) to image and visualize the distrib...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lydian A. Huisman, Pieter J. Steinkamp, Jan-Luuk Hillebrands, Clark J. Zeebregts, Matthijs D. Linssen, Annelies Jorritsma-Smit, Riemer H. J. A. Slart, Gooitzen M. van Dam, Hendrikus H. Boersma
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/90bcd3fa4abc46a1b524b9280ad22262
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:90bcd3fa4abc46a1b524b9280ad22262
record_format	dspace
spelling	oai:doaj.org-article:90bcd3fa4abc46a1b524b9280ad222622021-12-02T14:06:11ZFeasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW10.1038/s41598-021-82568-82045-2322https://doaj.org/article/90bcd3fa4abc46a1b524b9280ad222622021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82568-8https://doaj.org/toc/2045-2322Abstract Vascular endothelial growth factor-A (VEGF-A) is assumed to play a crucial role in the development and rupture of vulnerable plaques in the atherosclerotic process. We used a VEGF-A targeted fluorescent antibody (bevacizumab-IRDye800CW [bevacizumab-800CW]) to image and visualize the distribution of VEGF-A in (non-)culprit carotid plaques ex vivo. Freshly endarterectomized human plaques (n = 15) were incubated in bevacizumab-800CW ex vivo. Subsequent NIRF imaging showed a more intense fluorescent signal in the culprit plaques (n = 11) than in the non-culprit plaques (n = 3). A plaque received from an asymptomatic patient showed pathologic features similar to the culprit plaques. Cross-correlation with VEGF-A immunohistochemistry showed co-localization of VEGF-A over-expression in 91% of the fluorescent culprit plaques, while no VEGF-A expression was found in the non-culprit plaques (p < 0.0001). VEGF-A expression was co-localized with CD34, a marker for angiogenesis (p < 0.001). Ex vivo near-infrared fluorescence (NIRF) imaging by incubation with bevacizumab-800CW shows promise for visualizing VEGF-A overexpression in culprit atherosclerotic plaques in vivo.Lydian A. HuismanPieter J. SteinkampJan-Luuk HillebrandsClark J. ZeebregtsMatthijs D. LinssenAnnelies Jorritsma-SmitRiemer H. J. A. SlartGooitzen M. van DamHendrikus H. BoersmaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Lydian A. Huisman Pieter J. Steinkamp Jan-Luuk Hillebrands Clark J. Zeebregts Matthijs D. Linssen Annelies Jorritsma-Smit Riemer H. J. A. Slart Gooitzen M. van Dam Hendrikus H. Boersma Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW
description	Abstract Vascular endothelial growth factor-A (VEGF-A) is assumed to play a crucial role in the development and rupture of vulnerable plaques in the atherosclerotic process. We used a VEGF-A targeted fluorescent antibody (bevacizumab-IRDye800CW [bevacizumab-800CW]) to image and visualize the distribution of VEGF-A in (non-)culprit carotid plaques ex vivo. Freshly endarterectomized human plaques (n = 15) were incubated in bevacizumab-800CW ex vivo. Subsequent NIRF imaging showed a more intense fluorescent signal in the culprit plaques (n = 11) than in the non-culprit plaques (n = 3). A plaque received from an asymptomatic patient showed pathologic features similar to the culprit plaques. Cross-correlation with VEGF-A immunohistochemistry showed co-localization of VEGF-A over-expression in 91% of the fluorescent culprit plaques, while no VEGF-A expression was found in the non-culprit plaques (p < 0.0001). VEGF-A expression was co-localized with CD34, a marker for angiogenesis (p < 0.001). Ex vivo near-infrared fluorescence (NIRF) imaging by incubation with bevacizumab-800CW shows promise for visualizing VEGF-A overexpression in culprit atherosclerotic plaques in vivo.
format	article
author	Lydian A. Huisman Pieter J. Steinkamp Jan-Luuk Hillebrands Clark J. Zeebregts Matthijs D. Linssen Annelies Jorritsma-Smit Riemer H. J. A. Slart Gooitzen M. van Dam Hendrikus H. Boersma
author_facet	Lydian A. Huisman Pieter J. Steinkamp Jan-Luuk Hillebrands Clark J. Zeebregts Matthijs D. Linssen Annelies Jorritsma-Smit Riemer H. J. A. Slart Gooitzen M. van Dam Hendrikus H. Boersma
author_sort	Lydian A. Huisman
title	Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW
title_short	Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW
title_full	Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW
title_fullStr	Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW
title_full_unstemmed	Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW
title_sort	feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800cw
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/90bcd3fa4abc46a1b524b9280ad22262
work_keys_str_mv	AT lydianahuisman feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw AT pieterjsteinkamp feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw AT janluukhillebrands feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw AT clarkjzeebregts feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw AT matthijsdlinssen feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw AT anneliesjorritsmasmit feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw AT riemerhjaslart feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw AT gooitzenmvandam feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw AT hendrikushboersma feasibilityofexvivofluorescenceimagingofangiogenesisinnonculprithumancarotidatheroscleroticplaquesusingbevacizumab800cw
_version_	1718392034743549952

Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW

Ejemplares similares